Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 309

1.

Sputum cell counts to manage prednisone-dependent asthma: effects on FEV1 and eosinophilic exacerbations.

Aziz-Ur-Rehman A, Dasgupta A, Kjarsgaard M, Hargreave FE, Nair P.

Allergy Asthma Clin Immunol. 2017 Apr 4;13:17. doi: 10.1186/s13223-017-0190-0. eCollection 2017.

2.

The use of cellular and molecular biomarkers to manage COPD exacerbations.

Ho T, Dasgupta A, Hargreave FE, Nair P.

Expert Rev Respir Med. 2017 May;11(5):403-411. doi: 10.1080/17476348.2017.1307738. Epub 2017 Mar 27. Review.

PMID:
28347199
3.

Cytokine responses of peripheral blood mononuclear cells to allergen do not identify asthma or asthma phenotypes.

Simms E, Kjarsgaard M, Denis S, Hargreave FE, Nair P, Larché M.

Clin Exp Allergy. 2013 Nov;43(11):1226-35. doi: 10.1111/cea.12194.

PMID:
24152155
4.

Dose-dependent anti-inflammatory effect of inhaled mometasone furoate/formoterol in subjects with asthma.

Nolte H, Pavord I, Backer V, Spector S, Shekar T, Gates D, Nair P, Hargreave F.

Respir Med. 2013 May;107(5):656-64. doi: 10.1016/j.rmed.2013.02.010. Epub 2013 Mar 13.

5.

Quantitative sputum cell counts to monitor bronchitis: a qualitative study of physician and patient perspectives.

D'silva L, Neighbour H, Gafni A, Radford K, Hargreave F, Nair P.

Can Respir J. 2013 Jan-Feb;20(1):47-51.

6.

Local and systemic immunological parameters associated with remission of asthma symptoms in children.

Waserman S, Nair P, Snider D, Conway M, Jayaram L, McCleary LM, Dolovich J, Hargreave FE, Marshall JS.

Allergy Asthma Clin Immunol. 2012 Oct 8;8(1):16. doi: 10.1186/1710-1492-8-16.

7.

Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial.

Nair P, Gaga M, Zervas E, Alagha K, Hargreave FE, O'Byrne PM, Stryszak P, Gann L, Sadeh J, Chanez P; Study Investigators.

Clin Exp Allergy. 2012 Jul;42(7):1097-103. doi: 10.1111/j.1365-2222.2012.04014.x.

PMID:
22702508
8.

Persistent sputum cellularity and neutrophils may predict bronchiectasis.

Drost N, D'silva L, Rebello R, Efthimiadis A, Hargreave FE, Nair P.

Can Respir J. 2011 Jul-Aug;18(4):221-4.

9.

Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study.

Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, Wilkins HJ, Henkel T, Nair P; Res-5-0010 Study Group.

Am J Respir Crit Care Med. 2011 Nov 15;184(10):1125-32. doi: 10.1164/rccm.201103-0396OC. Epub 2011 Aug 18.

PMID:
21852542
10.

Lipid and smoker's inclusions in sputum macrophages in patients with airway diseases.

Wilson AM, Nair P, Hargreave FE, Efthimiadis AE, Anvari M, Allen CJ; ELVIS Research Study Group.

Respir Med. 2011 Nov;105(11):1691-5. doi: 10.1016/j.rmed.2011.07.011. Epub 2011 Aug 9.

11.

Heterogeneity of bronchitis in airway diseases in tertiary care clinical practice.

D'silva L, Hassan N, Wang HY, Kjarsgaard M, Efthimiadis A, Hargreave FE, Nair P.

Can Respir J. 2011 May-Jun;18(3):144-8.

12.

Asthma is not a syndrome.

Hargreave FE.

J Allergy Clin Immunol. 2011 Oct;128(4):904. doi: 10.1016/j.jaci.2011.05.021. No abstract available.

PMID:
21684586
13.

Point: Is measuring sputum eosinophils useful in the management of severe asthma? Yes.

Hargreave FE, Nair P.

Chest. 2011 Jun;139(6):1270-1273. doi: 10.1378/chest.11-0618. No abstract available.

PMID:
21652554
14.

Association between proximity to major roads and sputum cell counts.

Wallace J, D'silva L, Brannan J, Hargreave FE, Kanaroglou P, Nair P.

Can Respir J. 2011 Jan-Feb;18(1):13-8.

15.

Reproducibility, validity, and responsiveness of cell counts in blown nasal secretions.

Nair P, Goodwin S, Hargreave FE.

Allergy Rhinol (Providence). 2011 Jan;2(1):3-5. doi: 10.2500/ar.2011.2.0006.

16.
17.

Nitric oxide in exhaled breath is poorly correlated to sputum eosinophils in patients with prednisone-dependent asthma.

Nair P, Kjarsgaard M, Armstrong S, Efthimiadis A, O'Byrne PM, Hargreave FE.

J Allergy Clin Immunol. 2010 Aug;126(2):404-6. doi: 10.1016/j.jaci.2010.05.032. No abstract available.

PMID:
20621343
18.

Airway responsiveness to indirect challenges in COPD.

Hassan NM, Hargreave FE, Nair P.

COPD. 2010 Apr;7(2):133-40. doi: 10.3109/15412551003631741. Review.

PMID:
20397814
19.

Clinical equivalence testing of inhaled bronchodilators.

Nair P, Hanrahan J, Hargreave FE.

Pol Arch Med Wewn. 2009 Nov;119(11):731-5. Review.

20.

The definition and diagnosis of asthma.

Hargreave FE, Nair P.

Clin Exp Allergy. 2009 Nov;39(11):1652-8. doi: 10.1111/j.1365-2222.2009.03321.x. Epub 2009 Jul 20. Review.

PMID:
19622089
21.

Monitoring sputum eosinophils in mucosal inflammation and remodelling: a pilot study.

Chakir J, Loubaki L, Laviolette M, Milot J, Biardel S, Jayaram L, Pizzichini M, Pizzichini E, Hargreave FE, Nair P, Boulet LP.

Eur Respir J. 2010 Jan;35(1):48-53. doi: 10.1183/09031936.00130008. Epub 2009 Jul 16.

22.

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.

Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O'Byrne PM.

N Engl J Med. 2009 Mar 5;360(10):985-93. doi: 10.1056/NEJMoa0805435.

23.

Cost analysis of monitoring asthma treatment using sputum cell counts.

D'silva L, Gafni A, Thabane L, Jayaram L, Hassack P, Hargreave FE, Nair P.

Can Respir J. 2008 Oct;15(7):370-4.

24.

The effect of inhaled lidocaine-hydrofluoroalkane 134a in prednisone-dependent eosinophilic bronchitis.

Duong M, Wilson AM, Jayaram L, Dolovich M, Hargreave F.

Eur Respir J. 2008 Oct;32(4):1119-22. doi: 10.1183/09031936.00087108. No abstract available.

25.

Playing cards on asthma management: a new interactive method for knowledge transfer to primary care physicians.

Boulet LP, Borduas F, Bouchard J, Blais J, Hargreave FE, Rouleau M.

Can Respir J. 2007 Nov-Dec;14(8):480-4.

26.

Understanding allergic asthma from allergen inhalation tests.

Cockcroft DW, Hargreave FE, O'Byrne PM, Boulet LP.

Can Respir J. 2007 Oct;14(7):414-8. Review.

27.

Sputum neutrophilia can mask eosinophilic bronchitis during exacerbations.

D'silva L, Allen CJ, Hargreave FE, Parameswaran K.

Can Respir J. 2007 Jul-Aug;14(5):281-4.

28.

Cost-effectiveness of various diagnostic approaches for occupational asthma.

Kennedy WA, Girard F, Chaboillez S, Cartier A, Côté J, Hargreave F, Labrecque M, Malo JL, Tarlo SM, Redlich CA, Lemière C.

Can Respir J. 2007 Jul-Aug;14(5):276-80.

29.

Changing pattern of sputum cell counts during successive exacerbations of airway disease.

D'silva L, Cook RJ, Allen CJ, Hargreave FE, Parameswaran K.

Respir Med. 2007 Oct;101(10):2217-20. Epub 2007 Jul 2.

30.

Effect of obesity on airway inflammation: a cross-sectional analysis of body mass index and sputum cell counts.

Todd DC, Armstrong S, D'Silva L, Allen CJ, Hargreave FE, Parameswaran K.

Clin Exp Allergy. 2007 Jul;37(7):1049-54.

PMID:
17581198
31.

Effects of montelukast compared to double dose budesonide on airway inflammation and asthma control.

Barnes N, Laviolette M, Allen D, Flood-Page P, Hargreave F, Corris P, O'Connor B, Tate H, Parker D, Pavord I.

Respir Med. 2007 Aug;101(8):1652-8. Epub 2007 May 3.

32.

The efficiency of sputum cell counts in cystic fibrosis.

Jayaram L, Labiris NR, Efthimiadis A, Valchos-Mayer H, Hargreave FE, Freitag AP.

Can Respir J. 2007 Mar;14(2):99-103.

33.

Quantitative sputum cell counts as a marker of airway inflammation in clinical practice.

Hargreave FE.

Curr Opin Allergy Clin Immunol. 2007 Feb;7(1):102-6. Review.

PMID:
17218819
34.

Safety of sputum induction in moderate-to-severe smoking-related chronic obstructive pulmonary disease.

Wilson AM, Leigh R, Hargreave FE, Pizzichini MM, Pizzichini E.

COPD. 2006 Jun;3(2):89-93.

PMID:
17175671
35.

Asthma as a disease concept.

Hargreave FE, Leigh R, Parameswaran K.

Lancet. 2006 Oct 21;368(9545):1415-6. No abstract available.

PMID:
17055932
36.

Asthma, COPD and bronchitis are just components of airway disease.

Hargreave FE, Parameswaran K.

Eur Respir J. 2006 Aug;28(2):264-7. Review. No abstract available.

37.

Problems with using exhaled nitric oxide to guide asthma treatment.

Hargreave FE, Parameswaran K.

J Allergy Clin Immunol. 2006 Jun;117(6):1511; author reply 1511-2. No abstract available.

PMID:
16751027
38.

Eosinophilic bronchitis in asthma: a model for establishing dose-response and relative potency of inhaled corticosteroids.

Kelly MM, Leigh R, Jayaram L, Goldsmith CH, Parameswaran K, Hargreave FE.

J Allergy Clin Immunol. 2006 May;117(5):989-94. Epub 2006 Mar 31.

PMID:
16675323
39.

Predictors of loss of asthma control induced by corticosteroid withdrawal.

Belda J, Parameswaran K, Lemière C, Kamada D, O'Byrne PM, Hargreave FE.

Can Respir J. 2006 Apr;13(3):129-33.

40.

Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations.

Jayaram L, Pizzichini MM, Cook RJ, Boulet LP, Lemière C, Pizzichini E, Cartier A, Hussack P, Goldsmith CH, Laviolette M, Parameswaran K, Hargreave FE.

Eur Respir J. 2006 Mar;27(3):483-94.

41.

Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment.

Leigh R, Pizzichini MM, Morris MM, Maltais F, Hargreave FE, Pizzichini E.

Eur Respir J. 2006 May;27(5):964-71. Epub 2006 Jan 30.

42.

Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines.

Irwin RS, Baumann MH, Bolser DC, Boulet LP, Braman SS, Brightling CE, Brown KK, Canning BJ, Chang AB, Dicpinigaitis PV, Eccles R, Glomb WB, Goldstein LB, Graham LM, Hargreave FE, Kvale PA, Lewis SZ, McCool FD, McCrory DC, Prakash UBS, Pratter MR, Rosen MJ, Schulman E, Shannon JJ, Hammond CS, Tarlo SM.

Chest. 2006 Jan;129(1 Suppl):1S-23S. doi: 10.1378/chest.129.1_suppl.1S. No abstract available.

43.

Efficacy of fluticasone on cough.

Hargreave F, Parameswaran K.

Eur Respir J. 2005 Jul;26(1):181; author reply 181-2. No abstract available.

44.

Dosimeter: what is the dose?

Hargreave F.

Ann Allergy Asthma Immunol. 2005 Jan;94(1):14. No abstract available.

PMID:
15702809
45.

Steroid naive eosinophilic asthma: anti-inflammatory effects of fluticasone and montelukast.

Jayaram L, Pizzichini E, Lemière C, Man SF, Cartier A, Hargreave FE, Pizzichini MM.

Thorax. 2005 Feb;60(2):100-5.

46.

Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma.

Jayaram L, Duong M, Pizzichini MM, Pizzichini E, Kamada D, Efthimiadis A, Hargreave FE.

Eur Respir J. 2005 Jan;25(1):41-6.

47.

Effect of freezing of sputum samples on flow cytometric analysis of lymphocyte subsets.

Jaksztat E, Holz O, Paasch K, Kelly MM, Hargreave FE, Cox G, Magnussen H, Jörres RA.

Eur Respir J. 2004 Aug;24(2):309-12.

48.

An effective strategy for diagnosing occupational asthma: use of induced sputum.

Girard F, Chaboillez S, Cartier A, Côté J, Hargreave FE, Labrecque M, Malo JL, Tarlo SM, Lemière C.

Am J Respir Crit Care Med. 2004 Oct 15;170(8):845-50. Epub 2004 Jul 21.

PMID:
15271693
49.

Adult Asthma Consensus Guidelines update 2003.

Lemière C, Bai T, Balter M, Bayliff C, Becker A, Boulet LP, Bowie D, Cartier A, Cave A, Chapman K, Cowie R, Coyle S, Cockcroft D, Ducharme FM, Ernst P, Finlayson S, FitzGerald JM, Hargreave FE, Hogg D, Kaplan A, Kim H, Kelm C, O'Byrne P, Sears M, Markham AW; Canadian Adult Consensus Group of the Canadian Thoracic Society.

Can Respir J. 2004 May-Jun;11 Suppl A:9A-18A.

50.

A method to preserve sputum for delayed examination.

Kelly MM, Hargreave FE, Cox G.

Eur Respir J. 2003 Dec;22(6):996-1000.

Supplemental Content

Loading ...
Support Center